Starpharma Holdings Ltd. engages in the research, development, and commercialization of dendrimer products for pharmaceutical and healthcare applications. The principal activities of the Company consist of research, development and commercialization of dendrimer products for pharmaceutical and healthcare applications. Its portfolio of dendrimer-based products includes three clinical-stage DEP (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products. The company has developed a pipeline of novel DEP oncology products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, it has a preclinical pipeline of DEP radiopharmaceuticals and DEP Antibody-Drug Conjugates (ADCs) in development. Its VIRALEZE Nasal Spray is a broad-spectrum nasal spray intended to provide a protective barrier in the nose that traps and blocks cold/respiratory viruses. The company also offers VivaGel BV and VivaGel Condom products.
Follow-Up Questions
Qui est le CEO de Starpharma Holdings Ltd ?
Ms. Cheryl Maley est le Chief Executive Officer de Starpharma Holdings Ltd, il a rejoint l'entreprise depuis 2024.
Quelle est la performance du prix de l'action SPHRY ?
Le prix actuel de SPHRY est de $0.8448, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Starpharma Holdings Ltd ?
Starpharma Holdings Ltd appartient à l'industrie Pharmaceuticals et le secteur est Health Care
Quelle est la capitalisation boursière de Starpharma Holdings Ltd ?
La capitalisation boursière actuelle de Starpharma Holdings Ltd est de $353.3M
Est-ce que Starpharma Holdings Ltd est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour Starpharma Holdings Ltd, y compris 1 achat fort, 3 achat, 1 maintien, 0 vente et 1 vente forte
